skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Potential of anti-inflammatory treatment for cystic fibrosis lung disease

Review

(3300) Views  (869) Full article downloads

Authors: Jennifer L Taylor-Cousar, Kelsey A Von Kessel, Robert Young, et al

Published Date August 2010 Volume 2010:3 Pages 61 - 74
DOI: http://dx.doi.org/10.2147/JIR.S8875

Jennifer L Taylor-Cousar1,2, Kelsey A Von Kessel2, Robert Young1, David P Nichols1,2

1Department of Medicine, National Jewish Health, Denver, Colorado, USA; 2Department of Pediatrics, National Jewish Health, Denver, Colorado, USA

Abstract: Cystic fibrosis (CF) is the most common life-shortening genetic disorder in ­Caucasians. With improved diagnosis and treatment, survival has steadily increased. ­Unfortunately, the overwhelming majority of patients still die from respiratory failure caused by structural damage resulting from airway obstruction, recurrent infection, and inflammation. Here, we discuss the role of inflammation and the development of anti-inflammatory therapies to treat CF lung disease. The inflammatory host response is the least addressed component of CF airway disease at this time. Current challenges in both preclinical and clinical investigation make the identification of suitable anti-inflammatory drugs more difficult. Despite this, many researchers are making significant progress toward this goal and the CF research community has reason to believe that new therapies will emerge from these efforts.

Keywords: therapy, cystic fibrosis, survival, inflammation







Readers of this article also read:
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio